List view / Grid view
Amgen’s Lumykras® (sotorasib) has been approved for adults with advanced…
Amgen’s Lumykras® (sotorasib) has been approved for adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation.
Lumakras™ (sotorasib) demonstrated effective response rates against non-small cell lung…
Lumakras™ (sotorasib) demonstrated effective response rates against non-small cell lung cancer and colorectal cancer in Phase Ib trial.
Sotorasib combined with panitumumab displayed 27 percent response rate against…
Sotorasib combined with panitumumab displayed 27 percent response rate against colorectal cancer in Phase I/II trial.
Amgen’s Lumakras™, a KRAS inhibitor, was found to improve the…
Amgen’s Lumakras™, a KRAS inhibitor, was found to improve the stability of brain metastases in a Phase II study.
Marketing authorisation has been granted by the EC for Evenity®…
Marketing authorisation has been granted by the EC for Evenity® (romosozumab) to treat osteoporosis in postmenopausal women.
